This module uses fundamental data of Taysha Gene to approximate its Piotroski F score. Taysha Gene F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Taysha Gene Therapies. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Taysha Gene financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Taysha Gene Altman Z Score, Taysha Gene Correlation, Taysha Gene Valuation, as well as analyze Taysha Gene Alpha and Beta and Taysha Gene Hype Analysis.
Taysha
Piotroski F Score
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Investments
Stock Based Compensation
Begin Period Cash Flow
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Retained Earnings
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Total Current Assets
Capital Stock
Net Working Capital
Other Liab
Property Plant And Equipment Net
Net Debt
Accounts Payable
Cash
Cash And Short Term Investments
Capital Lease Obligations
Property Plant And Equipment Gross
Non Current Liabilities Other
Short Long Term Debt Total
Long Term Debt
Depreciation And Amortization
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Net Income Applicable To Common Shares
Income Tax Expense
Net Interest Income
Interest Income
Total Revenue
Gross Profit
Net Income From Continuing Ops
Cost Of Revenue
Reconciled Depreciation
Total Other Income Expense Net
Probability Of Bankruptcy
At present, Taysha Gene's Interest Debt Per Share is projected to increase slightly based on the last few years of reporting. The current year's Long Term Debt To Capitalization is expected to grow to 0.43, whereas Net Debt is forecasted to decline to (100 M). At present, Taysha Gene's PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's PB Ratio is expected to grow to 2.59, whereas Book Value Per Share is forecasted to decline to 0.71.
At this time, it appears that Taysha Gene's Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to Taysha Gene is to make sure Taysha is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Taysha Gene's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Taysha Gene's financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Taysha Gene's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Taysha Gene in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
0.71
At present, Taysha Gene's Book Value Per Share is projected to increase slightly based on the last few years of reporting.
Taysha Gene Current Valuation Drivers
We derive many important indicators used in calculating different scores of Taysha Gene from analyzing Taysha Gene's financial statements. These drivers represent accounts that assess Taysha Gene's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Taysha Gene's important valuation drivers and their relationship over time.
The Macroaxis Fundamental Analysis modules help investors analyze Taysha Gene Therapies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Taysha Gene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Taysha Gene Therapies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Taysha Gene Therapies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Taysha Gene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Taysha Gene Therapies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Taysha Gene Therapies Stock:
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Taysha Gene. If investors know Taysha will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Taysha Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.63
Revenue Per Share
0.042
Quarterly Revenue Growth
(0.62)
Return On Assets
(0.27)
Return On Equity
(1.15)
The market value of Taysha Gene Therapies is measured differently than its book value, which is the value of Taysha that is recorded on the company's balance sheet. Investors also form their own opinion of Taysha Gene's value that differs from its market value or its book value, called intrinsic value, which is Taysha Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Taysha Gene's market value can be influenced by many factors that don't directly affect Taysha Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Taysha Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taysha Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Taysha Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.